Experts in lymphomas, plasma cell disorders, myeloproliferative neoplasms, acute myeloid leukemia, myelodysplastic syndrome, and coagulation disorders will provide exciting updates from ASH 2021 with a focus on the latest treatment advances relevant to your clinical practice. The day will include presentations, case reviews, and interactive question and answer sessions.

EDUCATIONAL OBJECTIVES

By the end of the review, attendees will be better equipped to:

• Determine which patients with hematologic malignancy may benefit from specific targeted therapy
• Recognize myriad of presentations of patients with hematologic illnesses
• Identify higher-risk patients with hematologic malignancy and determine the best available therapies
• Understand the best current approach to patients requiring more aggressive treatments
• Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers, etc.)
• Manage complications of hematologic malignancies in an outpatient setting
• Familiarize health care practitioners with the latest updates as per clinical trial data in the proper diagnosis and treatment of benign hematologic diseases, such as sickle cell anemia, coagulopathies, and autoimmune hemolytic anemias. 

ACCREDITATION

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity. 

For more information please visit the official event page.